The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Subscribe To Our Newsletter & Stay Updated
